Rising Need of Whole Exome Sequencing

The whole-exome sequencing has been accepted as an advanced sequencing technique due to its advantages. Due to the benefits of whole-exome sequencing, it is used as a diagnostic tool in regular practice. The technique is mainly used to diagnose genetic diseases and cancer. The use of exome sequencing is offered genetic analysis that allows appropriate treatment, management, inheritance, and efficient decision making.

For Sample PDF - Click Here

The whole-exome sequencing technique is used as it provides information on clinically covered all genes. The technique analyzes conditions for single gene and multi gene disorders. The whole-exome sequencing technique is considered ideal for targeted management of complex conditions such as epilepsy, ASDs, neuropathy, and other genetic diseases. In addition, the whole-exome sequencing allows complete analysis of nearly 23,000 genes in the human genome with the help of next-generation sequencing in a single run.

Involving Top Companies:

Thermo Fisher Scientific Inc.
Illumina, Inc.
Centogene AG
F. Hoffmann-La Roche AG
Psomagen, Inc. (previuosly Macrogen Corp.)
Pacific Biosciences of California, Inc.
Brooks Automation, Inc. (GENEWIZ, Inc.)
Bio-Rad Laboratories, Inc.
Eurofins Scientific
Stratos Genomics

The whole-exome sequencing is a short-term substitute for receiving an image of a genome that is being coded. Whole-exome sequencing is attractive in the fields of research, diagnostics, and clinical setting. The whole-exome sequencing is used for identifying variants in both all the disease types and in SNPs associations and pharmacogenetics.

The advancement in the field of genomics has led to a significant reduction in the time and cost of genome sequencing. The related cost of sequencing with different sequencing techniques and strategies are of interest as they influence the scope and scale of the genomic research studies. Thus, it makes whole-exome sequencing much-preferred method than whole-genome sequencing.

The advantages of exome sequencing have resulted in the reduction of time and cost to a great extent. Approximately 2% of the genome is sequenced by the WES method; however, it generally sequences the exon at a deeper level it sequence to 100X. The technique enables sequencing through a process where the DNA and RNA are hybridized with the protein-coding site and is isolated from the non-coding site. Also, the data required for 100X sequencing is approximately 5- 6GB, whereas, in genome sequencing, it is nearly 90GB. Thus, these factors offer lower data storage, faster, cheaper, and more accessible data analysis. Therefore, owing to the above-mentioned factors, it is estimated that the market for whole-exome sequencing is likely to grow significantly during the forecast period.